CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
62.93
-4.00 (-5.98%)
At close: May 18, 2026, 4:00 PM EDT
63.39
+0.46 (0.73%)
Pre-market: May 19, 2026, 4:27 AM EDT
CG Oncology Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, CG Oncology stock has a consensus rating of "Strong Buy" and an average price target of $90.29. The average 1-year stock price forecast is 43.48% higher than the current stock price, while the lowest is $80 (+27.13%) and the highest is $108 (+71.62%).
Price Target: $90.29 (+43.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 4 |
| Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +58.91% | May 18, 2026 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $77 → $82 | Strong Buy | Reiterates | $77 → $82 | +30.30% | May 14, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $91 → $96 | Buy | Maintains | $91 → $96 | +52.55% | May 11, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $79 → $81 | Buy | Maintains | $79 → $81 | +28.71% | May 11, 2026 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $75 → $77 | Strong Buy | Reiterates | $75 → $77 | +22.36% | May 11, 2026 |
Financial Forecast
Revenue This Year
7.92M
from 4.04M
Increased by 96.09%
Revenue Next Year
117.92M
from 7.92M
Increased by 1,388.51%
EPS This Year
-2.77
from -2.08
EPS Next Year
-2.72
from -2.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 43.8M | 441.9M | ||||||
| Avg | 7.9M | 117.9M | ||||||
| Low | 980,000 | 39.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 984.0% | 5,478.0% | ||||||
| Avg | 96.1% | 1,388.5% | ||||||
| Low | -75.7% | 394.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.25 | -1.39 | ||||||
| Avg | -2.77 | -2.72 | ||||||
| Low | -3.01 | -3.61 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.